Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Ross

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Microbiology|July 21, 2012
Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibioticsJames E Ross, Helio S Sader, Zrinka Ivezic-Schoenfeld, et al.
Diagnostic Microbiology and Infectious Disease|November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum programDouglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|October 28, 2009
Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolatesRodrigo E Mendes, Ronald N Jones, Lalitagauri M Deshpande, et al.
International Journal of Antimicrobial Agents|June 22, 2005
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) ProgramTamara R Anderegg, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum ProgramJames E Ross, Tamara R Anderegg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 13, 2013
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|December 11, 2013
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United StatesRodrigo E Mendes, Robert K Flamm, Patricia A Hogan, et al.
Journal of Clinical Microbiology|January 12, 2007
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesDouglas J Biedenbach, James E Ross, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
Linezolid surveillance results for the United States: LEADER surveillance program 2011Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Microbiology|July 21, 2012
Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibioticsJames E Ross, Helio S Sader, Zrinka Ivezic-Schoenfeld, et al.
Diagnostic Microbiology and Infectious Disease|November 25, 2010
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum programDouglas J Biedenbach, David J Farrell, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|October 28, 2009
Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolatesRodrigo E Mendes, Ronald N Jones, Lalitagauri M Deshpande, et al.
International Journal of Antimicrobial Agents|June 22, 2005
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) ProgramTamara R Anderegg, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum ProgramJames E Ross, Tamara R Anderegg, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 13, 2013
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|December 11, 2013
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United StatesRodrigo E Mendes, Robert K Flamm, Patricia A Hogan, et al.
Journal of Clinical Microbiology|January 12, 2007
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesDouglas J Biedenbach, James E Ross, Thomas R Fritsche, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
Linezolid surveillance results for the United States: LEADER surveillance program 2011Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Pageof 4